公开(公告)号：US20060134119A1

公开(公告)日：2006-06-22

申请号：US10543193

申请日：2003-08-21

申请人： Mitsuomi Hirashima ,  Nozomu Nishi ,  Akira Yamauchi ,  Naoko Yoshida ,  Masako Seki

发明人： Mitsuomi Hirashima ,  Nozomu Nishi ,  Akira Yamauchi ,  Naoko Yoshida ,  Masako Seki

IPC分类号： A61K48/00 ,  A61K38/17 ,  A61K39/395

CPC分类号： A61K38/1709 ,  C07K16/18

摘要： Galectin 9 exerts various functions depending on its localizations. On the other hand, galectin 9 is expected as participating in various biological functions. Thus, it has been required to clarify the detailed biological activities of galectin 9 and develop galectin 9-related techniques including development of drugs. Human galectin 9 shows a cytotoxic activity and an apoptosis-inducing activity on tumor cells but shows neither cytotoxic activity nor apoptosis-inducing activity on normal cells. Therefore, it is possible to employ galectin 9 proteins, galectin 9 agonists, galectin 9 antagonists, anti-galectin 9 binding protein antibodies, anti-galectin 9 binding sugar chain antibodies, galectin 9-producing, releasing or inducing substances, etc. as antitumor, antiallergic, immunosuppressive agents, drugs for autoimmune diseases, anti-inflammatory agents and active ingredients for adrenocortical steroid hormone alternatives.

摘要翻译： Galectin 9根据其定位具有各种功能。 另一方面，半乳凝素9预期参与各种生物学功能。 因此，需要阐明半乳凝素9的详细生物学活性，并开发包含药物开发的半乳凝素9相关技术。 人半乳凝素9显示对肿瘤细胞的细胞毒活性和细胞凋亡诱导活性，但对正常细胞无细胞毒性活性或细胞凋亡诱导活性。 因此，可以使用半乳凝素9蛋白，半乳凝素9激动剂，半乳凝素9拮抗剂，抗半乳凝素9结合蛋白抗体，抗半乳凝素9结合糖链抗体，半乳凝素-9产生，释放或诱导物质等作为抗肿瘤剂 ，抗过敏药，免疫抑制剂，自身免疫性疾病药物，抗炎药和肾上腺皮质激素替代物的活性成分。

公开(公告)号：US20070042941A1

公开(公告)日：2007-02-22

申请号：US10554721

申请日：2004-04-28

申请人： Mitsuomi Hirashima ,  Nozomu Nishi ,  Akira Yamauchi ,  Naoko Yoshida ,  Masako Seki

发明人： Mitsuomi Hirashima ,  Nozomu Nishi ,  Akira Yamauchi ,  Naoko Yoshida ,  Masako Seki

IPC分类号： A61K38/17 ,  C07K14/47 ,  C07H21/04 ,  C12P21/06

CPC分类号： A61K38/1709 ,  C07K14/4726

摘要： It has been disclosed that Galectin 9, which is a physiologically active substance acting as a lectin, is expressed in various cells and a correlationship is observed between the expression level of galectin 9 and the metastatic ability of tumors. Therefore, it is presumed that galectin 9 would relate to various physiological phenomena. Thus, a substance allowing the control of galectin 9 production and release is expected as exerting an activity of inducing antitumor and/or anti-inflammatory actions, etc. Therefore, it is required to reveal the same. It has been found that a factor inducing the production and release of galectin 9, “galectin 9-inducing factor”, is contained in a certain solubilized tumor cell membrane fraction. This factor can be obtained as a concanavalin A-adsorbed fraction and as a concentrated active fraction by fractionation with an ion exchange column packed with Resource Q®, a hydroxyapatite column, etc. Assay reagents, drugs, assays, etc. can be developed by using the galectin 9-inducing activity of this factor.

摘要翻译： 已经公开了作为凝集素的生理活性物质的半乳凝素9在各种细胞中表达，并且在半乳凝素9的表达水平与肿瘤的转移能力之间观察到相关性。 因此，推测半乳凝素9与各种生理现象有关。 因此，预期能够控制半乳凝素9的产生和释放的物质具有诱导抗肿瘤和/或抗炎作用的活性等。因此，需要显示它。 已经发现，诱导半乳凝素9的产生和释放的因子“半乳凝素9诱导因子”被包含在某些溶解的肿瘤细胞膜级分中。 可以通过用填充有Resource Q（R），羟基磷灰石柱等的离子交换柱进行分级，作为伴刀豆素A吸附级分和作为浓缩的活性级分获得该因子。可以使用测定试剂，药物，测定等 通过使用该因子的半乳凝素9诱导活性开发。